The Santa Monica, Calif.-based company said that the uplisting follows its receipt of FDA 510(k) clearance for its Pure EP electrophysiology system.
BioSig said that the PureEP system is designed for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing electrocardiographic and intracardiac signals for patients undergoing electrophysiology procedures.
“We are extremely pleased to be stepping onto the Nasdaq Capital Market at this pivotal point. We begin trading on one of the world’s finest exchanges with a strong balance sheet, world-class IP, a leadership team with deep clinical and commercial expertise and support of several of the leading medical centers of excellence in our country. Our management and the board of directors believe that listing on the Nasdaq enables us to expand our shareholder base and provide access to a broader range of institutional investors worldwide as we commence targeted commercialization in the U.S., ultimately leading to the increase of shareholder value,” chair & CEO Kenneth Londoner said in a press release.
The company added that it recently received its first units from its contract manufacturer Minnetronix.
Last month, BioSig Technologies said that it raised $4.1 million in a new round of equity and warrants financing.